Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes

AIMS: To compare the efficacy and safety of an intensification strategy of early triple combination therapy with dapagliflozin (DAPA) plus saxagliptin (SAXA) to a dual therapy strategy with sitagliptin (SITA) in patients with type 2 diabetes who are inadequately controlled with metformin (MET) monot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Obes Metab
Main Authors: Handelsman, Yehuda, Mathieu, Chantal, Del Prato, Stefano, Johnsson, Eva, Kurlyandskaya, Raisa, Iqbal, Nayyar, Garcia‐Sanchez, Ricardo, Rosenstock, Julio
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6667916/
https://ncbi.nlm.nih.gov/pubmed/30499237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13594
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados